Trials / Conditions / Lymphoma, Large-Cell, Anaplastic

Lymphoma, Large-Cell, Anaplastic

17 registered clinical trials studyying Lymphoma, Large-Cell, Anaplastic.

Status	Trial	Sponsor	Phase
Active Not Recruiting	A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers NCT06254495	Seagen, a wholly owned subsidiary of Pfizer	Phase 1
Terminated	A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers NCT06120504	Seagen, a wholly owned subsidiary of Pfizer	Phase 1
Withdrawn	Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-deliver NCT05106192	Case Comprehensive Cancer Center	N/A
Terminated	A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic NCT04644315	Hoffmann-La Roche	Phase 2
Completed	A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clini NCT03942263	Takeda	—
Completed	T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas NCT03049449	National Cancer Institute (NCI)	Phase 1
Completed	Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Sy NCT02939014	Takeda	Phase 2
Active Not Recruiting	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (T NCT02568267	Hoffmann-La Roche	Phase 2
Completed	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral NCT01449461	Ariad Pharmaceuticals	Phase 1 / Phase 2
Completed	A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30- NCT01309789	Seagen Inc.	Phase 1
Completed	Cardiac Safety Study of Brentuximab Vedotin (SGN-35) NCT01026233	Seagen Inc.	Phase 1
Completed	Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) NCT01026415	Seagen Inc.	Phase 1
Completed	A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study NCT00947856	Seagen Inc.	Phase 2
Completed	A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma NCT00866047	Seagen Inc.	Phase 2
Terminated	A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignan NCT00649584	Seagen Inc.	Phase 1
Completed	Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies NCT00430846	Seagen Inc.	Phase 1
No Longer Available	A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 o NCT01196208	Seagen Inc.	—